Cooper Companies Drops Sharply as Surgical Review Disappoints

• Our read: The Cooper Companies, Inc is graded D by EasyAlpha while 62.5% of 16 analyst ratings are buys, with the dividend offsetting earnings quality among Healthcare peers in the S&P 500.
• The day: The shares tumbled 6.2% to close at $63.48 on Wednesday, September 9 after the company concluded its strategic review by keeping its surgical unit.
• Watching: The distance to the 52-week low of $58.89, which sits 7.8% below Wednesday's close.

Shares of Cooper Companies dropped sharply on Wednesday, falling 6.2% to $63.48. The decline came as the company concluded its strategic review by deciding to retain its CooperSurgical business, disappointing market expectations for a potential divestiture of the division. Investors had closely watched the outcome of the strategic review heading into the session, adding pressure to shares that had already weakened over the prior month.

Wednesday's decline was the second-largest daily drop for the stock over the past year, with trading volume reaching 5.7x its 20-session average. The selloff extended a losing run to three consecutive sessions, leaving the shares -16.8% over the past month and -22.5% so far this year.

EasyAlpha grades the company D among healthcare peers in the S&P 500. Across EasyAlpha's historical data, companies graded A or B have demonstrated stronger fundamentals and carried a lower risk of large drawdowns than companies graded D or E. That grade is a historical quality assessment, not a forecast for any individual stock.

Underlying financials illustrate the company's operating picture. Quarterly revenue grew +7.9%, with a profit margin of 5.6% and a return on equity of 2.9%. The shares trade at a trailing price-to-earnings ratio of 59.0. While Wall Street analysts maintain an average price target of $81.50, the stock's valuation and below-average grade highlight the tension between market expectations and peer-relative fundamentals.